Obermatt
See Similar Stocks →

Lonza

VTX:LONN · CH0013841017
Life Sciences Tools & ServicesX-Large

360

54
EV / EBIT35
Price / Owner Earnings92
Owner Earnings Yield1
Dividend Yield49
Price/Sales22
EV / Gross Profit21
Price/Book27
Return on Capital63
Cash Return on Capital31
Return on Equity66
EBIT Margin75
Gross Profitability19
Accruals67
Owner Earnings Margin25
Sales growth76
Profit Growth82
Long-Term EPS Growth75
Reinvestment37
Price momentum30
Debt load36
Refinancing63
Debt Payback1
Liquidity65
Analyst ratings79
Opinion Changes53
Price Target Upside83
Market mood94
Value Creation8/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Lonza clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountrySwitzerland
IndustryLife Sciences Tools & Services
SizeX-Large
TypePublic Company
ExchangeSWX
Founded1897
Employees14,251
Websitelonza.com
ISINCH0013841017
Last UpdateApr 2, 2026
Indices
SMI (Switzerland)SPI (Switzerland)
Themes
Stem Cell TherapyNutraceuticalGeneticsImmunologyVaccines

Description

Lonza Group AG is a preferred global partner to the pharmaceutical, biotech, and nutrition markets. The company harnesses scientific innovation and manufacturing technology to enable customers to serve patients and consumers effectively. The company…

Analysis

Middle-of-the-road

Lonza Group AG sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is moderate; the safety picture is adequate. The company scores 8/20 on our value-creation score: creating some value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
79
202320242026

All-time high

94

Mar 2026

All-time low

3

Jan 2023

Average rank

52

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
22
—
21
11
Price/Earnings
23
—
22
7
Price/Book
27
—
45
30
Dividend Yield
49
—
39
26
Value (overall)
25
—
19
9

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Lonza with its peers
Sartorius Stedim
PAR:DIM
15
CountryGermany
IndustryLife Sciences Tools & Services
SizeLarge
Full Stock Analysis →
ChemoMetec
CPH:CHEMM
83
CountryDenmark
IndustryLife Sciences Tools & Services
SizeSmall
Full Stock Analysis →
Sanofi India
NSI:SANOFI
56
CountryFrance
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Enlivex Therapeutics
NAQ:ENLV
68
CountryIsrael
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Merck (DE)
GER:MRK
12
CountryGermany
IndustryPharmaceuticals
SizeXX-Large
Full Stock Analysis →
BioNTech
NSQ:BNTX
11
CountryGermany
IndustryBiotechnology
SizeLarge
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →